Logo

Santhera Reports Results of Raxone (Idebenone) in P-III DELOS trial for Patients with Duchenne Muscular Dystrophy (DMD)

Share this

Santhera Reports Results of Raxone (Idebenone) in P-III DELOS trial for Patients with Duchenne Muscular Dystrophy (DMD)

Shots:

  • The P-III DELOS trial involves assessing of idebenone (900mg/day) vs PBO in 64 patients with DML for 52 wks.
  • P-III DELOS study results: 50% reduction in annual rates of forced vital capacity; treatment effect remained 6 yrs.; reduction in risk of important patient-relevant outcomes including bronchopulmonary AEs and hospitalizations; reductions in the rate of both inspiratory and expiratory respiratory function loss
  • Idebenone is a benzoquinone and a cofactor for the enzyme NAD(P)H H quinone oxidoreductase (NQO1) approved for Leber's hereditary optic neuropathy (LHON) in the EU including n- Norway- Iceland- Liechtenstein- Israel and Serbia

Ref: Santhera Pharmaceuticals | Image: Twitter

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions